查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1421682

神經生物標記市場、份額、規模、趨勢、行業分析報告：按類型、按應用、按最終用途、按地區、按細分市場、預測，2024-2032 年

Neurological Biomarkers Market Share, Size, Trends, Industry Analysis Report, By Type (Metabolomic, Genomic, Imaging, Proteomic, Others); By Application; By End-Use; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 115 Pages | 商品交期: 最快1-2個工作天內

價格

根據Polaris Market Research的最新研究，到2032年，全球神經生物標記市場規模預計將達到248.3億美元。 該報告提供了對當前市場動態的詳細見解，並對未來市場成長進行了分析。

神經生物標記可作為測量和評估症狀並確定對特定治療的藥理反應的指標。 廣泛應用於自閉症、帕金森氏症、憂鬱症等多種疾病的診斷。 這些生物標記分為幾個類別，包括代謝組學、成像、基因組學和蛋白□□質組學。

神經生物標記（包括特徵生物標記）的進步正在提高神經系統疾病治療的有效性，加速藥物開發，實現早期診斷並促進非侵入性檢測。 此外，數位生物標記正在為製藥公司提供有價值的補充資訊並幫助臨床試驗決策，從而推動神經生物標記市場的成長。

在個人化醫療領域，神經退化性疾病的神經生物標記研究進展迅速，大量分子正在被評估並與各種神經退化性疾病相關。 精準醫療的這種演變正在對生物製藥行業產生重大影響，並為從生物製藥公司到診斷公司、從商業運營到研發的各種參與者帶來重大變化。

然而，較長的生物標記開發週期和較高的啟動成本可能會阻礙市場成長。 從正面的方面來看，由於有機構在不同的研究階段提供資金，因此市場擴張有充足的機會。 值得注意的是，美國國立衛生研究院 (NIH) 已撥款額外資金支持與阿茲海默症和大腦老化的健康差異相關的研究，進一步刺激市場成長。

此外，國家醫學圖書館 2021 年 6 月發表的一項研究強調了冠狀動脈疾病 (CAD) 對全球健康的重大影響。 光是 CAD 每年就導致約 61 萬人死亡，佔估計死亡人數的四分之一，是美國的第一大死因。 隨著 CAD 發病率的增加，對有效的神經生物標記設備來滿足這一緊迫的醫療需求的需求不斷增長。 因此，預計該因素將在整個預測期內推動對神經生物標記的需求。

神經生物標記物市場報告亮點

  • 蛋白質體學領域將在2022年獲得最高的收入份額蛋白質組學生物標記物發揮著舉足輕重的作用，特別是當僅僅依靠mRNA表達無法揭示多種翻譯後修飾的功能意義時。我會實現它。 在這種情況下，蛋白質組生物標記對於透過密切檢測蛋白質特徵和翻譯後修飾的變化來準確診斷疾病的發病和進展至關重要。 這些生物標記在揭示阿茲海默症 (AD) 等複雜且無法解釋的疾病背後的細胞變化方面顯示出顯著的功效。 AD 的重要蛋白質體生物標記包括膠質纖維酸性蛋白 (GFAP)、銅鋅超氧化物歧化□ (SOD1)、AB42、tau 和 AB 勝□。 新產品的不斷推出預計將推動市場成長。
  • 阿茲海默症在 2022 年佔據了最大的市場份額，預計在預測期內將繼續佔據主導地位。 這一趨勢主要是由於這種疾病的盛行率不斷增加以及人們越來越重視早期診斷和及時治療。
  • 到 2022 年，北美將成為最大市場。 北美神經生物標記市場佔據重要份額，預計在即將到來的預測期內將呈現顯著的複合年增長率。 這種增長是由多種因素推動的，包括神經系統疾病的高盛行率以及旨在支持該行業的政府舉措的激增。 此外，市場有望受益於新產品的推出和對生物標記物需求的增加。 該地區積極資助研究和創新生物標記開發，進一步促進市場擴張。

目錄

第一章簡介

第 2 章執行摘要

第三章研究方法

第 4 章全球神經生物標記市場洞察

  • 神經生物標記物市場 - 應用快照
  • 神經生物標記物市場動態
    • 推動者和機會
      • 神經系統疾病的發生率增加
      • 增加對生物標記研發 (R&D) 的投資
    • 抑制因素和挑戰
      • 初始投資成本高，生物標記開發週期長
  • PESTEL 分析
  • 神經生物標記物市場應用趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第五章全球神經生物標記市場，依類型

  • 主要發現
  • 簡介
  • 代謝組學
  • 基因組
  • 成像
  • 蛋白質體學
  • 其他

第 6 章全球神經生物標記市場（依最終用途）

  • 主要發現
  • 簡介
  • 獨立臨床診斷中心
  • 研究機構等
  • 醫院和醫院實驗室

第 7 章全球神經生物標記市場（按應用）

  • 主要發現
  • 簡介
  • 自閉症譜系障礙
  • 帕金森氏症
  • 阿茲海默症
  • 多發性硬化症
  • 其他

第 8 章全球神經生物標記市場（按地區）

  • 主要發現
  • 簡介
    • 神經生物標記市場評估，地區，2019-2032
  • 神經生物標記市場 - 北美
    • 北美：神經生物標記物市場（按類型），2019-2032 年
    • 北美：神經生物標記市場，按應用劃分，2019-2032 年
    • 北美：神經生物標記市場，依最終用途，2019-2032 年
    • 神經生物標記市場 - 美國
    • 神經生物標記市場 - 加拿大
  • 神經生物標記市場 - 歐洲
    • 歐洲：神經生物標記市場（按類型），2019-2032 年
    • 歐洲：神經生物標記物市場，按應用劃分，2019-2032 年
    • 歐洲：神經生物標記市場，依最終用途分類，2019-2032 年
    • 神經生物標記市場 - 英國
    • 神經生物標記市場 - 法國
    • 神經生物標記市場 - 德國
    • 神經生物標記市場 - 義大利
    • 神經生物標記市場 - 西班牙
    • 神經生物標記市場 - 荷蘭
    • 神經生物標記市場 - 俄羅斯
  • 神經生物標記市場 - 亞太地區
    • 亞太地區：神經生物標記市場（按類型），2019-2032 年
    • 亞太地區：神經生物標記市場，按應用劃分，2019-2032 年
    • 亞太地區：神經生物標記市場，依最終用途，2019-2032 年
    • 神經生物標記市場 - 中國
    • 神經生物標記市場 - 印度
    • 神經生物標記市場 - 馬來西亞
    • 神經生物標記物市場 - 日本
    • 神經生物標記市場 - 印度尼西亞
    • 神經生物標記物市場 - 韓國
  • 神經生物標記市場 - 中東和非洲
    • 中東和非洲：神經生物標記市場（按類型），2019-2032 年
    • 中東和非洲：神經生物標記市場，按應用劃分，2019-2032 年
    • 中東和非洲：神經生物標記市場（以最終用途），2019-2032 年
    • 神經生物標記市場 - 沙烏地阿拉伯
    • 神經生物標記市場 - 阿拉伯聯合大公國
    • 神經生物標記市場 - 以色列
    • 神經生物標記市場 - 南非
  • 神經生物標記市場 - 拉丁美洲
    • 拉丁美洲：神經生物標記市場（按類型），2019-2032 年
    • 拉丁美洲：神經生物標記市場，按應用劃分，2019-2032 年
    • 拉丁美洲：神經生物標記市場，依最終用途劃分，2019-2032 年
    • 神經生物標記市場 - 墨西哥
    • 神經生物標記市場 - 巴西
    • 神經生物標記市場 - 阿根廷

第九章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協議/揭露

第十章公司簡介

  • Abbott
  • Alseres Pharmaceuticals, Inc.
  • BANYAN BIOMARKERS, INC.
  • Bio-Rad Laboratories, Inc.
  • DiaGenic ASA
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Quanterix
  • Thermo Fisher Scientific, Inc.
Product Code: PM4022

The global neurological biomarkers market size is expected to reach USD 24.83 billion by 2032, according to a new study by Polaris Market Research. The report "Neurological Biomarkers Market Share, Size, Trends, Industry Analysis Report, By Type (Metabolomic, Genomic, Imaging, Proteomic, Others); By Application; By End-Use; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Neurological biomarkers serve as indicators for measuring and assessing symptoms or determining a pharmacological response to a specific treatment. They find extensive application in the diagnosis of various conditions, including autism, Parkinson's disease, and depression. These biomarkers fall into several categories, including metabolomics, imaging, genomics, and proteomics.

Advancements in neurological biomarkers, encompassing signature biomarkers, are enhancing the effectiveness of treating neurological diseases, expediting drug development, enabling early diagnosis, and facilitating noninvasive testing. Furthermore, digital biomarkers are supplying valuable supplementary information to pharmaceutical companies, aiding in clinical trial decision-making and, consequently, propelling the growth of the neurological biomarkers market.

In the realm of personalized medicine, neurological biomarker research for neurodegenerative diseases represents a rapidly advancing field, with numerous molecules being associated and evaluated in the context of various neurodegenerative disorders. This evolution in precision medicine is significantly influencing the biopharmaceutical industry, leading to substantial transformations across various players, from biopharma to diagnostics companies, with roles ranging from commercial operations to research and development.

Even with this, the market's growth may be hindered by protracted biomarker development cycles and substantial startup costs. On a positive note, the presence of organizations offering funding at various research stages presents ample opportunities for market expansion. Notably, the National Institutes of Health (NIH) is allocating additional funds to support research related to health disparities in Alzheimer's and brain aging, further stimulating market growth.

Additionally, a study published in the National Library of Medicine in June 2021 highlighted the significant impact of coronary artery disease (CAD) on global health. CAD alone is responsible for approximately 610,000 deaths annually, accounting for an estimated one in four deaths and making it the foremost cause of mortality in the United States. With the incidence of CAD rising, there is a growing demand for effective Neurological Biomarkers devices to address this pressing medical need. Consequently, this factor is projected to drive the demand for Neurological Biomarkers throughout the forecast period.

Neurological Biomarkers Market Report Highlights

  • In 2022, the Proteomic segment dominated with the highest revenue share. Proteomic biomarkers play a pivotal role, especially when relying solely on mRNA expression falls short in revealing the functional implications of diverse post-translational modifications. In such scenarios, proteomic biomarkers become indispensable for accurately diagnosing the onset and progression of diseases by meticulously detecting protein signatures and post-translational changes. These biomarkers have demonstrated remarkable effectiveness in unveiling the cellular alterations underlying complex and unexplained conditions like Alzheimer's disease (AD). Prominent proteomic biomarkers for AD include glial fibrillary acidic protein (GFAP), copper-zinc superoxide dismutase (SOD1), AB42, tau, and AB peptides. The continuous introduction of new products is expected to be a driving force behind market growth.
  • Alzheimer's disease secured the largest market share in 2022 and is expected to continue its dominance during the forecast period. This trend is mainly driven by the rising prevalence of the disease and a heightened focus on early diagnosis and prompt treatment.
  • In 2022, North America took the lead as the largest market. The neurological biomarkers market in North America holds a substantial share and is expected to exhibit a noteworthy CAGR in the upcoming forecast period. This growth is underpinned by several factors, including the high prevalence of neurological disorders and the surge in government initiatives aimed at supporting this sector. Moreover, the market is set to gain from a growing influx of new product launches and an increasing demand for biomarkers. The region maintains robust funding for research and the development of innovative biomarkers, further contributing to market advancement.
  • The global key market players include: Abbott, Alseres Pharmaceuticals, Inc., BANYAN BIOMARKERS, INC., Bio-Rad Laboratories, Inc., DiaGenic ASA, Johnson & Johnson Services, Inc., Merck & Co., Inc., Myriad Genetics, Inc., Quanterix, Thermo Fisher Scientific, Inc.

Polaris Market Research has segmented the Neurological Biomarkers market report based on type, application, end-use, and region:

Neurological Biomarkers, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Metabolomic
  • Genomic
  • Imaging
  • Proteomic
  • Others

Neurological Biomarkers, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Autism Spectrum Disorder
  • Parkinson's Disease
  • Alzheimer's Disease
  • Multiple Sclerosis
  • Others

Neurological Biomarkers, End-Use Outlook (Revenue - USD Billion, 2019 - 2032)

  • Independent clinical diagnostic centers
  • Research Organizations and Others
  • Hospital & Hospital Laboratories

Neurological Biomarkers, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Neurological Biomarkers Market Insights

  • 4.1. Neurological Biomarkers Market - Application Snapshot
  • 4.2. Neurological Biomarkers Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Incidence of Neurological Disorders
      • 4.2.1.2. Elevated investment in Research and Development (R&D) for biomarkers
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High initial investment expenses and lengthy biomarker development cycles
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Neurological Biomarkers Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Neurological Biomarkers Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Metabolomic
    • 5.3.1. Global Neurological Biomarkers Market, by Metabolomic, by Region, 2019-2032 (USD Billion)
  • 5.4. Genomic
    • 5.4.1. Global Neurological Biomarkers Market, by Genomic, by Region, 2019-2032 (USD Billion)
  • 5.5. Imaging
    • 5.5.1. Global Neurological Biomarkers Market, by Imaging, by Region, 2019-2032 (USD Billion)
  • 5.6. Proteomic
    • 5.6.1. Global Neurological Biomarkers Market, by Proteomic, by Region, 2019-2032 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Neurological Biomarkers Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Neurological Biomarkers Market, by End Use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • 6.3.Independent clinical diagnostic centers
    • 6.3.1. Global Neurological Biomarkers Market, by Independent clinical diagnostic centers, by Region, 2019-2032 (USD Billion)
  • 6.4. Research Organizations and Others
    • 6.4.1. Global Neurological Biomarkers Market, by Research Organizations and Others, by Region, 2019-2032 (USD Billion)
  • 6.5. Hospital & Hospital Laboratories
    • 6.5.1. Global Neurological Biomarkers Market, by Hospital & Hospital Laboratories, by Region, 2019-2032 (USD Billion)

7. Global Neurological Biomarkers Market, by Application

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 7.3. Autism Spectrum Disorder
    • 7.3.1. Global Neurological Biomarkers Market, by Autism Spectrum Disorder, By Region, 2019-2032 (USD Billion)
  • 7.4. Parkinson's Disease
    • 7.4.1. Global Neurological Biomarkers Market, by Parkinson's Disease, By Region, 2019-2032 (USD Billion)
  • 7.5. Alzheimer's Disease
    • 7.5.1. Global Neurological Biomarkers Market, by Alzheimer's Disease, By Region, 2019-2032 (USD Billion)
  • 7.6. Multiple Sclerosis
    • 7.6.1. Global Neurological Biomarkers Market, by Multiple Sclerosis, By Region, 2019-2032 (USD Billion)
  • 7.7. Others
    • 7.7.1. Global Neurological Biomarkers Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Neurological Biomarkers Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Neurological Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Neurological Biomarkers Market - North America
    • 8.3.1. North America: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.3.3. North America: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.3.4. Neurological Biomarkers Market - U.S.
      • 8.3.4.1. U.S.: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.3.5. Neurological Biomarkers Market - Canada
      • 8.3.5.1. Canada: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • 8.4. Neurological Biomarkers Market - Europe
    • 8.4.1. Europe: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.4. Neurological Biomarkers Market - UK
      • 8.4.4.1. UK: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.5. Neurological Biomarkers Market - France
      • 8.4.5.1. France: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.6. Neurological Biomarkers Market - Germany
      • 8.4.6.1. Germany: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.7. Neurological Biomarkers Market - Italy
      • 8.4.7.1. Italy: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.8. Neurological Biomarkers Market - Spain
      • 8.4.8.1. Spain: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.9. Neurological Biomarkers Market - Netherlands
      • 8.4.9.1. Netherlands: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.10. Neurological Biomarkers Market - Russia
      • 8.4.10.1. Russia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • 8.5. Neurological Biomarkers Market - Asia Pacific
    • 8.5.1. Asia Pacific: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.4. Neurological Biomarkers Market - China
      • 8.5.4.1. China: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.5. Neurological Biomarkers Market - India
      • 8.5.5.1. India: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.6. Neurological Biomarkers Market - Malaysia
      • 8.5.6.1. Malaysia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.7. Neurological Biomarkers Market - Japan
      • 8.5.7.1. Japan: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.8. Neurological Biomarkers Market - Indonesia
      • 8.5.8.1. Indonesia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.9. Neurological Biomarkers Market - South Korea
      • 8.5.9.1. South Korea: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • 8.6. Neurological Biomarkers Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.4. Neurological Biomarkers Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.5. Neurological Biomarkers Market - UAE
      • 8.6.5.1. UAE: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.6. Neurological Biomarkers Market - Israel
      • 8.6.6.1. Israel: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.7. Neurological Biomarkers Market - South Africa
      • 8.6.7.1. South Africa: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • 8.7. Neurological Biomarkers Market - Latin America
    • 8.7.1. Latin America: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.7.4. Neurological Biomarkers Market - Mexico
      • 8.7.4.1. Mexico: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.7.5. Neurological Biomarkers Market - Brazil
      • 8.7.5.1. Brazil: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.7.6. Neurological Biomarkers Market - Argentina
      • 8.7.6.1. Argentina: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Alseres Pharmaceuticals, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. BANYAN BIOMARKERS, INC.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Bio-Rad Laboratories, Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. DiaGenic ASA
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Johnson & Johnson Services, Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Merck & Co., Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Myriad Genetics, Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Quanterix
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Thermo Fisher Scientific, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables

  • Table 1 Global Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 3 Global Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 4 Neurological Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 7 North America: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 8 U.S.: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 10 U.S.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 11 Canada: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 13 Canada: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 14 Europe: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 16 Europe: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 17 UK: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 19 UK: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 20 France: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 22 France: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 23 Germany: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 25 Germany: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 26 Italy: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 28 Italy: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 29 Spain: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 31 Spain: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 35 Russia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 37 Russia: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 41 China: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 43 China: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 44 India: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 46 India: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 50 Japan: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 52 Japan: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 56 South Korea: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 58 South Korea: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 65 UAE: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 67 UAE: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 68 Israel: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 70 Israel: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 71 South Africa: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 73 South Africa: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 74 Latin America: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 76 Latin America: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 77 Mexico: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 79 Mexico: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 80 Brazil: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 82 Brazil: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 83 Argentina: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 85 Argentina: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Neurological Biomarkers Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by End Use
  • Figure 7. Global Neurological Biomarkers Market, by End Use, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Neurological Biomarkers Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Application
  • Figure 11. Global Neurological Biomarkers Market, by Application, 2022 & 2032 (USD Billion)
  • Figure 12. Neurological Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Neurological Biomarkers Market